u/TheVirginVibes

3 theses · first seen Sep 4, 2026

Window	Theses	Resolved	Wins	Win rate	Avg return	Median return
1d	2	2	1	50%	+0.7%	+0.7%
3d	2	2	1	50%	-0.7%	-0.7%
1w	2	2	0	0%	-3.6%	-3.6%
1m	2	2	1	50%	-5.0%	-5.0%
3m	0	0	0	—	—	—
6m	0	0	0	—	—	—
1y	0	0	0	—	—	—

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$BLRXr/pennystocksBullishbullish

u/TheVirginVibes · 10h ago2 prior · awaiting results

BLRX - BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

BioLineRx has a near-term catalyst stack with SNO presentations on November 13 covering GBM preclinical and Phase 1/2a trial design, followed by ESMO ovarian cancer/PARP inhibitor synergy data. Multiple clinical milestones through H1 2027 including Phase 1 human efficacy and PDAC interim results provide upside drivers.

At post $2.21Now $2.210.0% since postedas of Oct 8, 4:30 PM ET

original post →

$BLRXr/pennystocksStock Infobullish

u/TheVirginVibes · 36d ago2 prior · awaiting results

Joseph Pantginis Reiterates Buy on $BLRX (BiolineRX) as GLIX1 and CheMo4METPANC Advance and APHEXDA Royalties Support Funding Through 1H 2027

H.C. Wainwright analyst reiterates Buy on Bioline RX with $26 price target, citing advancement of first-in-class DDR agent GLIX1 through Phase 1/2a glioblastoma trials, pipeline expansion into additional tumor types, and APHEXDA royalties funding operations through mid-2027.

At post $2.74Now $2.21-19.3% since postedas of Oct 8, 4:30 PM ET

1d-1.8%

3d-2.6%

1w-6.9%

1m-13.5%

3m—

6m—

1y—

original post →

$BLRXr/pennystocksStock Infobullish

u/TheVirginVibes · 80d ago2 prior · awaiting results

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

GLIX1 demonstrates synergy with PARP inhibitors in HR-proficient ovarian cancer, potentially expanding a $50B+ addressable market currently controlled by AstraZeneca's $5B olaparib. Multiple cancer indications in development (brain, pancreatic) with near-term catalysts (earnings Aug 13, pancreatic interim data, GBM Phase 1 H1 2027) and $15M market cap suggest significant upside as the drug becomes recognized as a platform therapy.

At post $2.83Now $2.21-21.9% since postedas of Oct 8, 4:30 PM ET

1d+3.2%

3d+1.1%

1w-0.4%

1m+3.5%

3m—

6m—

1y—

original post →

End of results.